This data brief uses procurement records published by the U.S. Department of Defense and China’s People’s Liberation Army between April and November of 2020 to assess, and, where appropriate, compare what each military is buying when it comes to artificial intelligence. We find that the two militaries are prioritizing similar application areas, especially intelligent and autonomous vehicles and AI applications for intelligence, surveillance and reconnaissance.

An expert assessment of Chinese scientific literature validates China's public claim to be working toward artificial general intelligence (AGI). At a time when other nations are contemplating safeguards on AI research, China’s push toward AGI challenges emerging global norms, underscoring the need for a serious open-source monitoring program to serve as a foundation for outreach and mitigation.

Vaccines keep the U.S. public healthy while safeguarding economic stability and biosecurity. This report assesses the domestic vaccine manufacturing landscape and identifies two major vulnerabilities: a reliance on foreign manufacturers and a lack of manufacturing redundancy. Maintaining a resilient vaccine supply will require the U.S. government to take steps to protect the existing supply, identify and monitor manufacturing vulnerabilities, and create a stronger domestic production base.

In late 2020, China established the Beijing Institute for General Artificial Intelligence, a state-backed institution dedicated to building software that emulates or surpasses human cognition in many or all of its aspects. Open source materials now available provide insight into BIGAI’s goals, scope, organization, methodology, and staffing. The project formalizes a trend evident in Chinese AI development toward broadly capable (general) AI.

Pandemic threats are increasing as globalization, urbanization, and encroachment on animal habitats cause infectious outbreaks to become more frequent and severe. It is imperative that the United States build a pipeline of medical countermeasure development, beginning with basic scientific research and culminating in approved therapies. This report assesses preparedness for families of viral pathogens of pandemic potential and offers recommendations for steps the U.S. government can take to prepare for future pandemics.

CSET Director of Biotechnology Programs Anna Puglisi testified before the U.S.-China Economic and Security Review Commission at a hearing on "China’s Challenges and Capabilities in Educating and Training the Next Generation Workforce."

China’s government has pushed the country’s technology and financial firms to expand abroad, and Southeast Asia’s growing economies — and AI companies — offer promising opportunities. This report examines the scope and nature of Chinese investment in the region. It finds that China currently plays a limited role in Southeast Asia’s emerging AI markets outside of Singapore and that Chinese investment activity still trails behind that of the United States. Nevertheless, Chinese tech companies, with support from the Chinese government, have established a broad range of other AI-related linkages with public and commercial actors across Southeast Asia.

CSET's Dr. Caroline Schuerger, Dr. Steph Batalis, and Vikram Venkatram submitted this comment with recommendations for the National Biotechnology and Biomanufacturing Initiative.

China is rapidly building cyber ranges that allow cybersecurity teams to test new tools, practice attack and defense, and evaluate the cybersecurity of a particular product or service. The presence of these facilities suggests a concerted effort on the part of the Chinese government, in partnership with industry and academia, to advance technological research and upskill its cybersecurity workforce—more evidence that China has entered near-peer status with the United States in the cyber domain.

Biosafety Level-3 laboratories (BSL-3) are an essential part of research infrastructure and are used to develop vaccines and therapies. The research conducted in them provides insights into host-pathogen interactions that may help prevent future pandemics. However, these facilities also potentially pose a risk to society through lab accidents or misuse. Despite their importance, there is no comprehensive list of BSL-3 facilities, or the institutions in which they are housed. By systematically assessing PubMed articles published in English from 2006-2021, this paper maps institutions that host BSL-3 labs by their locations, augmenting current knowledge of where high-containment research is conducted globally.